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AbstrAct
Background  Type 2 diabetes may alter cardiac structure 
and function. Many patients with type 2 diabetes have 
diastolic dysfunction with preserved ejection fraction (EF). 
Recently, this latter measure was criticised. Thus, this 
research looked at the impact of left ventricular end-
diastolic volume and E/e′ ratio variations in patients 
with type 2 diabetes and preserved EF with the aim to 
recognise different clinical phenotypes.
Methods  In this cross-sectional study, we evaluated 
176 men affected by type 2 diabetes with transthoracic 
echocardiography. All subjects have preserved EF (>50%). 
Patients were stratified into four groups based on the 
median value of both left ventricular end-diastolic volume 
and E/e′ ratio, and the clinical variables were registered. 
The independent predictors associated with the groups 
were analysed by a multinomial logistic regression model.
Results Diabetes duration, age, estimated glomerular 
filtration rate and antihypertensive treatments were 
significantly different among the groups as were EF, left 
atrial volume index (LAVI), E/A, septum thickness and s′ 
mean wave. Multinomial regression analysis showed that 
the groups significantly differed for age, diabetes duration, 
EF, LAVI, septum thickness and s′ mean wave. The main 
result of this study was that patients with higher left 
ventricular volume and higher E/e′ ratio (group 2) showed 
the worse clinical profile.
Conclusions Our study might suggest that variations 
of left ventricular end-diastolic volume along with E/e′ 
ratio variations, even in the normal range, may allow to 
recognise phenotypes of patients with type 2 diabetes with 
worse clinical characteristics. This finding should be tested 
in prospective studies to assess the predictive roles of 
these phenotypes.
InTRoduCTIon
Diabetes mellitus is a well-known risk factor 
for the development of heart alterations 
both in the structure and in the function.1 2 
The Framingham Heart Study demonstrated 
that the frequency of heart failure is five 
times higher in diabetic women and two 
times greater in diabetic men compared 
with age-matched control subjects.3 The 
most frequent heart alteration in type 2 
diabetes is heart failure with preserved 
ejection fraction (EF).4 However, heart 
failure with preserved EF was recently ques-
tioned5 6 as the EF parameter alone roughly 
reflects heart performance.7 A MRI study 
found lower left ventricular (LV) EF, higher 
values of troponin and other surrogate 
markers of cardiovascular risk in patients 
with left ventricular end-diastolic volume 
(LVEDV) dilation compared with those 
without LVEDV dilation independently of 
left ventricular hypertrophy (LVH) pattern, 
concentric or eccentric.8 Consequently, the 
authors suggested reclassifying concentric 
and eccentric LVH into two further groups 
based on the absence or presence of LVEDV 
dilation.8
Early diastolic dysfunction is generally 
referable to an impaired relaxation filling 
significance of this study
What is already known about this subject?
 ► Type 2 diabetes may alter both heart structure and 
function.
 ► Heart failure is an increasing complication of type 
2 diabetes.
 ► Left ventricular end-diastolic volume modification 
may be an early marker of alteration of left ventric-
ular geometry.
What are the new findings?
 ► The main result of this study is that phenotyping 
patients with  type 2 diabetes with left ventricular 
end-diastolic volume and E/e′ ratio may help to cat-
egorise patients in groups with different clinical and 
echocardiographic characteristics.
How might these results change the focus of 
research or clinical practice?
 ► If confirmed in a prospective setting, our results may 
help to recognise patients with type 2 diabetes at 
very high risk of developing heart failure.
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pattern in patients with preserved LVEF.9 As reported in 
the recommendations for the evaluation of LV diastolic 
function, it is the combination of elevated LV diastolic 
pressure and the absence of an increased LVEDV that 
represents a strong evidence in favour of well-devel-
oped diastolic dysfunction.10 It may be misleading to 
consider isolated diastolic dysfunction without inves-
tigating LV dimension, as LV dilation is an important 
aspect of LV geometric remodelling.7 8
Evidences showed that standard echocardiographic 
parameters, such as left ventricular end-diastolic 
volume and E/e′ ratio, are well validated from the 
pathophysiological and prognostic points of view.11 
Therefore, we believe that heart failure with preserved 
EF may be a quite heterogeneous class and we hypoth-
esise that stratification according to diastolic filling 
pressure estimated (E/e′ ratio) and LVEDV may help 
to categorise type 2 diabetes patients.7 11 Consequently, 
the aim of this study was to test whether stratification 
of patients affected by type 2 diabetes with preserved 
LVEF according to E/e′ ratio and LVEDV would be able 
to separate different phenotypes.
MeTHods
subjects
In order to reduce the overall variability of the echo-
cardiographic measures, we studied only white men 
affected by type 2 diabetes. The sample of the present 
study was composed of 176 adult male ambulatory 
patients, out of 215. Ischaemic heart diseases, revas-
cularisation and/or chronic heart failure, valvular 
heart diseases, atrial fibrillation or atrial flutter, a prior 
history of cirrhosis, malignancy or overt nephropathy, 
EF below 50% and absence of some variables were 
considered exclusion criteria.
Clinical and laboratory variables
Clinical data (duration of diabetes, body mass index 
and blood pressure) were collected and patients were 
considered to have hypertension if their blood pressure 
was ≥140/90 mm Hg or if they were taking some antihy-
pertensive drugs. Venous blood samples were drawn in 
the morning after an overnight fast. Serum creatinine 
(measured using a Jaffé rate-blanked and compensated 
assay) and other biochemical blood measurements were 
determined using standard laboratory procedures (DAX 
96; Bayer Diagnostics, Milan, Italy). Low-density lipo-
protein cholesterol was calculated using the Friedewald 
equation. Haemoglobin A1c (HbA1c) was measured 
by an automated high-performance liquid chromatog-
raphy analyser (HA-8140; Menarini Diagnostics, Flor-
ence, Italy). The glomerular filtration rate (eGFRCKD-EPI) 
was estimated by the CKD Epidemiology Collaboration 
(CKD-EPI) equation.12 Albuminuria was measured by an 
immuno-nephelometric method on a morning spot urine 
sample and expressed as the albumin:creatinine ratio. A 
single ophthalmologist diagnosed diabetic retinopathy 
using funduscopy after pupillary dilation according to a 
clinical disease severity scale (no retinopathy, non-pro-
liferative, proliferative or laser-treated retinopathy); the 
presence of proliferative retinopathy was confirmed 
by fundus fluorescein angiography. Nephropathy was 
defined as the presence of eGFR <60 mL/min/1.73 m2 
and/or abnormal albuminuria (ie, an albumin:-creati-
nine ratio ≥30 mg/g creatinine). For all participants, the 
presence of retinopathy or nephropathy was recorded as 
microvascular complication, whereas the absence of both 
complications included those subjects in the category 
without microvascular complications.
echocardiography
Transthoracic echocardiographic Doppler evalua-
tion with spectral tissue Doppler analysis (Vivid 7; GE 
Vingmed, Horten, Norway) were performed in all patients 
by two experienced cardiologists who were blinded to 
the participants’ details. Conventional echocardiography 
was used to measure LV diameters, wall thickness and 
mass according to standard criteria. LV end-diastolic and 
end-systolic volumes and LVEF at rest were measured 
at the apical four-chamber and two-chamber views (by 
modified Simpson rule).13 Left atrial volume index 
(LAVI) maximal volume was measured at the end of LV 
systole from the apical four-chamber and two-chamber 
views (maximum LA size) using the modified Simpson 
rule.13 LAVI was calculated as LA volume divided by 
the body surface area. Pulsed-wave Doppler was used to 
measure trans-mitral peak early diastolic velocity (E), 
peak late diastolic velocity (A) and E-wave deceleration 
time (DTe). Each value was obtained from the average 
of three measurements. Pulsed-wave tissue Doppler echo-
cardiography of the septal and lateral mitral annulus was 
used to measure the early peak (e′), and the mean values 
of septal and lateral annulus measurements were used for 
analysis (e mean wave).14
In a previous study,15 we have shown that when tissue 
Doppler imaging signals were remeasured by the same 
observer, the mean absolute differences (±SD) in tissue 
velocities within the same observer was 0.19±0.17 cm/s 
for e′ velocity (p=NS).
Heart failure with preserved ejection fraction (HFpEF) 
was considered when patients present a LVEF above or 
equal to 50%.2
study design
This cross-sectional study sought to assess whether differ-
ences in clinical and echocardiographic features existed 
between patients with type 2 diabetes according to the 
presence of variations in LVEDV and in E/e′ ratio, esti-
mates of modifications of LV geometry or LV filling 
pressures, respectively. Four defined groups were thus 
constituted based on the median value of both LVEDV/
body surface area (BSA (56 mL/m2) and averaged E/e′ 
ratio,8 as reported in figure 1. Subjects with LVEDV/
BSA <56 mL/m2 and averaged E/e′ <8 were considered 
(group 0) ‘normal’ and used as reference category in a 
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Figure 1 Categorisation of subjects in four groups according to median values of left ventricular end-diastolic volume (LVEDV) 
mL/m2 and E/e′. Group 0: LVEDV/body surface area (BSA) <56 mL/m2 and averaged E/e′ ≤8; group 1: LVEDV/BSA ≥56 mL/m2 
and averaged E/e′ ≤8; group 2: LVEDV/BSA ≥56 mL/m2 and averaged E/e′ >8; group 3: LVEDV/BSA <56 mL/m2 and averaged 
E/e′ >8.
Cardiovascular and Metabolic Risk
multinomial regression model to assess the variables asso-
ciated with the different groups.
statistical analysis
Data are summarised as means±SD or percentages. 
Differences in clinical/biochemical characteristics and 
echocardiographic parameters among groups of patients 
were compared by the one-way analysis of variance for 
normally distributed variables and the non-parametric 
tests for non-normally distributed variables. The χ2 test 
was used for categorical variables to study differences 
in proportions or percentages between the groups. To 
estimate the independent predictors of different pheno-
types, a multinomial logistic regression analysis was 
performed with group 0 as the reference category. Age, 
duration of diabetes, eGFRCKDEPI, glycosylated haemo-
globin, EF E/A, LAVI, septum thickness and s′ mean wave 
velocity were included as covariates. Covariates for this 
multinomial logistic regression model were chosen as 
potential confounding factors based on their significance 
in univariate analyses. The bivariate correlation between 
septum thickness and LV mass/BSA was highly significant 
(r=0.635, p<0.001), and we included only the septum 
thickness in the multinomial model. A p value<0.05 was 
assumed to indicate a statistical significance.
ResulTs
We studied 176 men affected by type 2 diabetes with no 
cardiovascular diseases and preserved ejection fraction 
(LVEF >50 %) by echocardiography. Considering that 
the elevated LV diastolic filling pressure with normal 
LV end-diastolic volume is a strong evidence in favour 
of well-developed diastolic dysfunction, we categorised 
subjects according to the median value of LVEDV/BSA 
(56 mL/m2) and the median value of E/e′ ratio,8 respec-
tively. Therefore, as shown in figure 1, we obtained four 
phenotypic groups, with group 3 highly indicative of 
diastolic dysfunction (increased diastolic filling pressure 
with a normal LVEDV) and group 2 with both increased 
diastolic filling pressure and higher LVEDV. Subjects 
with LVEDV/BSA <56 mL/m2 and E/e′ <8 were consid-
ered (group 0) ‘normal’ and used as reference category, 
while groups 1 and 2 showed higher LVEDV. Only very 
few subjects (3,9%) had a LVEDV above 74 mL/m2, thus 
satisfying the clinical cut-off for LV dilation.10
Table 1 reports clinical characteristics of the subjects 
subdivided into the four phenotypic groups. Subjects in 
group 3 were the oldest, while the longest duration of 
diabetes was detected in group 2, it being 9–10 years (in 
average) longer than that of subjects of group 0. Subjects 
in group 2 showed also the lowest eGFR value, a higher 
prevalence of subjects treated for hypertension and a 
tendency to a higher prevalence of subjects with retinop-
athy. Glycaemic control and lipids levels were compa-
rable among the groups. Oral hypoglycaemic agents were 
taken by 63.4% of patients, none of them were treated 
with pioglitazone or SGLT2 inhibitors, while 31.5% were 
on insulin treatment, and 20% were treated with insulin 
associated to an oral hypoglycaemic agent. Antihyperten-
sive therapy was reported in 71.8% of patients, while 43% 
were on statin treatment.
The echocardiographic characteristics are reported in 
table 2. The lowest values of EF were observed in subjects 
in group 2 and in group 1. E/A ratio was significantly 
different among the four groups and the indexes of 
systolic performance, annular S′ waves, were lower in 
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Table 1  Descriptive statistics for the clinical characteristics of male subjects with type 2 diabetes mellitus stratified by 
groups
Group 0
(n=53)
Group 1
(n=41)
Group 2
(n=43)
Group 3
(n=39) P values
Age, years 64.1±8.8 67.3±7.0 68.5±8.0 70.0±6.4 0.003
Diabetes duration, years 8.4±9.4 10.5±8.2 17.9±11.2 15.2±9.2 <0.001
BMI, kg/m2 28.3±4.0 28.1±3.9 28.9±4.6 27.8±2.9 0.559
Pulse pressure, mm Hg 57.5±12.5 64.7±16.5 65.3±12.0 65.3±14.3 0.011
HbA1c, mmol/mol 52.7±8.7 53.6±9.2 57.0±17.0 57.8±11.5 0.118
Total cholesterol, mmol/L 4.5±1.0 4.2±0.9 4.3±1.0 4.4±1.0 0.494
LDL cholesterol, mmol/L 2.7±0.9 2.3±0.8 2.4±0.8 2.5±0.8 0.083
HDL cholesterol, mmol/L 1.19±0.29 1.19±0.30 1.18±0.29 1.24±0.28 0.775
Triglycerides, mmol/L 1.7±0.7 1.5±0.8 1.6±0.7 1.6±0.7 0.838
eGFRCKD-EPI, mL/min/1.73 m
2 84.6±14.5 86.2±11.0 75.6±22.1 80.7±13.7 0.009
Hypertension   86.8%   82.9%   97.7%   89.7% 0.157
Retinopathy, of any degree   15.1%   4.9%   25.6%   15.4% 0.074
Nephropathy   24.5%   31.7%   34.9%   28.2% 0.716
Current smoker   45.3%   31.7%   25.6%   33.3% 0.288
Insulin therapy   39.6%   24.4%   34.9%   46.2% 0.218
Antihypertensive therapy   62.5%   61.0%   86.0%   82.1% 0.011
Values are means±SD, percentages or medians (IQR). Hypertension was defined as blood pressure ≥140/90 mm Hg or use of any 
antihypertensive drugs. Nephropathy was defined as the presence of eGFR <60 mL/min/1.73 m2 and/or abnormal albuminuria. Group 0: 
LVEDV/BSA <56 mL/m2 and averaged E/e′ ≤8; group 1: LVEDV/BSA ≥56 mL/m2 and averaged E/e′ ≤8; group 2: LVEDV/BSA ≥56 mL/m2 and 
averaged E/e′ >8; group 3: LVEDV/BSA <56 mL/m2 and averaged E/e′ >8.
BMI, body mass index; BSA, body surface area; eGFRCKD-EPI, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; LVEDV, left ventricular end-diastolic volume.
Table 2  Echocardiographic characteristics of male subjects with type 2 diabetes mellitus stratified by groups
Group 0
(n=53)
Group 1
(n=41)
Group 2
(n=43)
Group 3
(n=39) P values
LV ejection fraction, % 67.2±7.7 61.2±4.8 59.8±4.8 64.7±5.7 <0.001
S′septum, cm/s 9.4±2.0 9.3±2.2 8.0±1.3 8.3±1.6 <0.001
S′lateral, cm/s 10.5±2.5 10.0±2.2 9.2±2.2 8.7±1.8 0.003
Septum thickness, mm 11.4±1.4 11.6±1.3 12.3±1.2 12.0±1.5 0.007
E/A ratio 0.77±0.22 0.74±0.17 0.89±0.23 0.77±0.14 0.003
Deceleration time, ms 241.4±62.9 266.0±74.2 244.9±51.6 252.7±66.0 0.297
E/e′ ratio 6.3±1.3 6.5±1.3 10.7±1.9 9.9±1.9   NA
LVEDV/BSA, mL/m2 47.5 64.0 64.5 48.4   NA
LA volume index, mL/m2 24.0±6.8 31.2±6.0 35.2±8.2 30.6±9.4 <0.001
LV mass/BSA*, g/m2 129.5±27.8 129.5±24.6 144.1±22.7 137.3±26.5 0.025
Relative wall thickness 0.43±0.05 0.41±0.07 0.43±0.06 0.43±0.05 0.432
Values are means±SD or percentages. Group 0: LVEDV/BSA <56 mL/m2 and averaged E/e′ ≤8; group 1: LVEDV/BSA ≥56 mL/m2 and 
averaged E/e’ ≤8; group 2: LVEDV/BSA ≥56 mL/m2 and averaged E/e′ >8; group 3: LVEDV/BSA <56 mL/m2 and averaged E/e′ >8.
*LV mass/BSA was calculated using the following formula: (0.8×(1.04×(LVDd+IVSd+PWd)3−(LVDd)3))+0.6/body surface area (28).
BSA, body surface area; LA, left atrial; LV, left ventricular; LVEDV, left ventricular end-diastolic volume.
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subjects in groups 2 and 3. LA volume index was signifi-
cantly higher in subjects of group 2. Septum thickness 
and LV mass were higher in groups 2 and 3. No differ-
ences were noticed in relative wall thickness.
In order to identify factors associated with the different 
phenotypes, we performed a multinomial logistic regres-
sion analyses with different phenotypes as dependent 
variable (group 0 was the reference phenotype), as shown 
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Table 3  Multinomial logistic regression analysis investigating factors associated with groups
Reference group0
Group 1
OR (95% CI) P values
Group 2
OR (95% CI) P values Group 3 P values
Age, years 1.10 (1.00 to 1.21) 0.042 1.12 (0.97 to 1.25) 0.058 1.16 (1.04 to 1.30) 0.010
Diabetes duration, years 0.99 (0.91 to 1.08) 0.731 1.09 (1.00 to 1.18) 0.041 1.06 (0.98 to 1.13) 0.139
HbA1c 1.08 (0.53 to 2.20) 0.831 0.66 (0.26 to 1.65) 0.373 1.60 (0.81 to 3.17) 0.181
eGFRCKD-EPI, mL/min/1.73 m
2 1.03 (0.97 to 1.09) 0.294 1.00 (0.94 to 1.06) 0.888 1.03 (0.98 to 1.09) 0.233
Ejection fraction 0.83 (0.75 to 0.93) 0.001 0.82 (0.72 to 0.93) 0.002 0.96 (0.88 to 1.05) 0.415
E/A 1.07 (0.74 to 1.56) 0.705 2.14 (1.39 to 3.31) 0.001 1.54 (1.03 to 2.31) 0.035
Septum thickness (mm) 1.04 (0.69 to 1.57) 0.851 1.78 (1.06 to 2.99) 0.030 1.41 (0.90 to 2.23) 0.106
LA volume index, mL/m2 1.16 (1.05 to 1.27) 0.003 1.18 (1.06 to 1.31) 0.002 1.09 (0.99 to 2.19) 0.131
S′mean, cm/s 1.05 (0.77 to 1.44) 0.755 0.71 (0.45 to 1.11) 0.134 0.60 (0.39 to 0.92) 0.019
Data are expressed as OR and 95% CI. Group 0: LVEDV/BSA <56 mL/m2 and averaged E/e′ ≤8; group 1: LVEDV/BSA ≥56 mL/m2 and 
averaged E/e′ ≤8; group 2: LVEDV/BSA ≥56 mL/m2 and averaged E/e′ >8; group 3: LVEDV/BSA <56 mL/m2 and averaged E/e′ >8. Values in 
bold are statistically significant results.
eGFRCKD-EPI, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; LA, left atrial.
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in table 3. Age was a significant predictor associated with 
all groups, while diabetes duration was significant only in 
group 2. Decreasing EF and increasing LAVI were signif-
icant predictors in groups 1 and 2 compared with group 
0; both groups have a higher LVED. E/A ratio was a signif-
icant predictor in groups 2 and 3. Septum thickness was 
a significant predictor in group 2, while a reduction of 
S′ mean wave was a significant predictor in group 3. The 
inclusion of either antihypertensive therapy (0=no therapy; 
1=therapy) or retinopathy (0=no retinopathy; 1=retinop-
athy) in the model does not change the results.
dIsCussIon
The results of the present study suggest that in patients 
affected by type 2 diabetes with preserved EF and without 
cardiovascular diseases, a higher LVEDV may iden-
tify different phenotypes of subjects. Our classification 
appears to differentiate subjects according to clinical and 
echocardiographic parameters. Notably, the different 
phenotypes were predicted by different factors in multi-
nomial logistic regression analysis. In detail, in subjects 
of group 2 (increase in both LVEDV/BSA and E/e′), the 
main associated predictors were diabetes duration, LAVI 
and EF; also, the septum thickness was significantly asso-
ciated with this group. Regarding the latter association, it 
is interesting to note that subjects of group 2 were more 
frequently treated with antihypertensive therapy. Subjects 
of group 3, those who ideally represent the real diastolic 
dysfunction with increased diastolic filling pressure and 
normal LVEDV, showed as main predictors the S′ mean 
wave and E/A ratio. The factors significantly associated 
to group 1 were EF and LAVI. It appears that subjects 
belonging to group 2 have the worse clinical profile with 
a diabetes of longer duration, a lower eGFRCKD-EPI (16.3% 
of subjects in this group showed a eGFRCKD-EPI below 60 
mL/min/1.73 m2 compared with 7.7% in group 0, 2.4% 
in group 1% and 10.3% in group 3), a higher pulse 
pressure, more frequently treated for hypertension and 
a higher prevalence of retinopathy.
Recent studies conducted in patients with hyperten-
sion suggested that LV dilation could identify different 
phenotypes of LV hypertrophy showing differences in both 
biomarkers of cardiac performances and prognosis.16 17
Therefore, in the present study, we tested the hypoth-
esis whether LVEDV may identify different phenotypes of 
patients with type 2o diabetes.
LVEDV is an important parameter of cardiac geom-
etry and even a small increase in volume may have prog-
nostic relevance, as previously shown. A higher LVEDV 
was shown to independently predict trastuzumab-related 
cardiotoxicity in patients with HER2-positive early breast 
cancer.18 In an initially untreated large sample of subjects 
with hypertension, those with LV dilation, regardless 
of the hypertrophy pattern, experienced a worse prog-
nosis compared with subjects without LV dilation.19 20 
The authors of the Dallas study suggested to subdivide 
eccentric and concentric LVH into two subgroups based 
on the presence or absence of LV dilation.16 In this study, 
subjects with LV dilation were at higher risk of cardio-
vascular death and heart failure compared with those 
without LV dilation.16
However, not all studies confirmed the prognostic 
impact of LV dilation over the LV mass,21 but perhaps 
this study did not have enough events .
Our study seems to indicate that LVEDV dilation, even 
though in a normal range, in type 2 diabetes may iden-
tify patients with different characteristics. More notable, 
patients in groups 2 and 3 who differ only for a LVEDV/
BSA higher or lower than 56 mL/m2 but with a similar 
ventricular filling pressure showed similar duration of 
diabetes and metabolic control level but differed for 
EF and S′ mean wave, while subjects in group 1 with 
LVEDV similar to group to 2 but with a normal ventric-
ular filling pressure showed a significant shorter duration 
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of diabetes. These data may suggest that the pathway of 
cardiac involvement in diabetes might follow different 
directions: one leading to dilation and the other to 
diastolic dysfunction. LVEDV may represent the initial 
bifurcation in this pathway, and it may appear earlier 
than the diastolic dysfunction. It would be extremely 
interesting to test this hypothesis in a longitudinal setting 
with cardiac death and heart failure as outcomes in type 
2 diabetes.
Moreover, in a recent study by our group, we also 
reported an inverse correlation between metabolic 
control and subclinical systolic dysfunction22 that may 
also suggest that a better metabolic control could slow 
the progression of e cardiac disease in type 2 diabetes.
An interesting and recent study by using the cluster 
analysis on the echocardiographic parameters identified 
three clusters of cardiac phenotypes: one with low comor-
bidity, a second with elderly and diastolic dysfunction and 
a third phenotype with hypertrophic systolic dysfunction. 
Interestingly, the first cluster showed the lowest value of 
E/e′ and these patients are similar to those of our group 
0, while the third cluster showed the highest left ventric-
ular volume and the lowest strain and these patients are 
similar to those of our group 2.23
Therefore, considering that the more frequent presen-
tation when the dominant problem is diabetes consists 
in a setting characterised by abnormal systolic function, 
as shown by longitudinal strain, despite normal EF,24 the 
results of our study may have clinical relevance. In fact, a 
finding of an increasing LVEDV may herald a very initial 
change in LV geometry that can influence the prog-
nosis of a patient; it would be interesting to test whether 
a potentiation of therapy at this point may hinder the 
evolution towards heart failure.
The study is limited by its own cross-sectional design 
that does allow inferences of the cause–effect relation-
ship, and the use of median value of LVEDV to categorise 
subjects instead of a clinical cut-off points of normalcies. 
However, it should be noted that 56 mL/m2 for LVEDV/
BSA is close to the mean value for this parameter (54 
mL/m2) reported in the recommendations for cardiac 
chamber quantification.10 Moreover, the absence of a 
control group does not allow to draw the conclusion of 
whether this is relevant for patients with type 2 diabetes or 
also for non-diabetic subjects. Finally, it should be pointed 
out that due to the low number of subjects in each group, 
the results should be interpreted with caution since there 
is a significant risk to find false associations. Nevertheless, 
our study has some strengths: all subjects had preserved 
EF and absence of cardiovascular diseases, they were all 
men eliminating interferences due to sex, and patients 
were well characterised with respect to diabetes and its 
complications.
In conclusion, our study might suggest that variations 
of LVEDV along with E/e′ ratio variations, even in the 
normal range, may allow to recognise phenotypes of 
type 2 diabetes patients with worse clinical characteris-
tics. This finding should be tested in further prospective 
studies to assess the possible predictive roles of these 
phenotypes.
Contributors GZ, GT, CB: conception, design and analysis and interpretation 
of data. GZ: drafting the manuscript. GT, SB, CB, AR, EB: revising critically the 
manuscript for important intellectual content. MT, LL, AM, LB, LZ, AT: contributed to 
the analysis and interpretation of data.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Obtained.
ethics approval The local ethics committee approved the study protocol.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement All data generated or analysed during this study are 
included in this published article.
open access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
REFERENCES
 1. Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol 
2017;120(1S):S37–S47.
 2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure: The 
Task Force for the diagnosis and treatment of acute and chronic 
heart failure of the European Society of Cardiology (ESC). Developed 
with the special contribution of the Heart Failure Association (HFA) of 
the ESC. Eur J Heart Fail 2016;18:891–975.
 3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The 
Framingham study. JAMA 1979;241:2035–8.
 4. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High 
prevalence of previously unknown heart failure and left ventricular 
dysfunction in patients with type 2 diabetes. Diabetologia 
2012;55:2154–62.
 5. Petrie MC, Caruana L, Berry C, et al. "Diastolic heart failure" or heart 
failure caused by subtle left ventricular systolic dysfunction? Heart 
2002;87:29–31.
 6. Lindman BR. The diabetic heart failure with preserved ejection 
fraction phenotype: is it real and is it worth targeting therapeutically? 
Circulation 2017;135:736–40.
 7. Konstam MA, Abboud FM. Ejection fraction: misunderstood and 
overrated (changing the paradigm in categorizing heart failure). 
Circulation 2017;135:717–9.
 8. Khouri MG, Peshock RM, Ayers CR, et al. A 4-tiered classification of 
left ventricular hypertrophy based on left ventricular geometry: the 
Dallas heart study. Circulation 2010;3:164–71.
 9. Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler 
echocardiography and tissue Doppler imaging in the estimation 
of diastolic function in heart failure with normal ejection fraction: a 
comparative Doppler-conductance catheterization study. Circulation 
2007;116:637–47.
 10. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac 
chamber quantification by echocardiography in adults: an update 
from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging. Eur Heart J Cardiovasc 
Imaging 2015;16:233–71.
 11. Galderisi M, Esposito R, Trimarco B. Cardiac involvement 
in diabetes: the dark side of the moon. J Am Coll Cardiol 
2017;70:1717–9.
 12. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney 
Disease Epidemiology Collaboration). A new equation to estimate 
glomerular filtration rate. Ann Intern Med 2009;150:604–12.
 13. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations 
for the evaluation of left ventricular diastolic function by 
echocardiography. J Am Soc Echocardiogr 2009;22:107–33.
 14. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations 
for the evaluation of left ventricular diastolic function by 
 o
n
 3 July 2018 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2018-000529 on 14 June 2018. Downloaded from 
7BMJ Open Diab Res Care 2018;6:e000529. doi:10.1136/bmjdrc-2018-000529
Cardiovascular and Metabolic Risk
echocardiography: an update from the American Society 
of Echocardiography and the European Association 
of Cardiovascular Imaging. J Am Soc Echocardiogr 
2016;29:277–314.
 15. Bonapace S, Targher G, Molon G, et al. Relationship between 
early diastolic dysfunction and abnormal microvolt T-wave 
alternans in patients with type 2 diabetes. Circ Cardiovasc Imaging 
2011;4:408–14.
 16. Khouri MG, Peshock RM, Ayers CR, et al. A 4-tiered classification of 
left ventricular hypertrophy based on left ventricular geometry: the 
Dallas heart study. Circ Cardiovasc Imaging 2010;3:164–71.
 17. Garg S, de Lemos JA, Ayers C, et al. Association of a 4-tiered 
classification of LV hypertrophy with adverse CV outcomes in the 
general population. JACC Cardiovasc Imaging 2015;8:1034–41.
 18. Bergamini C, Torelli F, Ghiselli L, et al. Left ventricular end-diastolic 
volume as early indicator of trastuzumab-related cardiotoxicity 
in HER2+ breast cancer patients: results from a single-center 
retrospective study. Minerva Cardioangiol 2017;65:278–87.
 19. Verdecchia P, Angeli F, Mazzotta G, et al. Impact of chamber 
dilatation on the prognostic value of left ventricular geometry in 
hypertension. J Am Heart Assoc 2017;246:pii: e005948.
 20. de Simone G, Izzo R, Aurigemma GP, et al. Cardiovascular risk 
in relation to a new classification of hypertensive left ventricular 
geometric abnormalities. J Hypertens 2015;33:745–54.
 21. Cuspidi C, Facchetti R, Bombelli M, et al. Risk of mortality in 
relation to an updated classification of left ventricular geometric 
abnormalities in a general population. J Hypertens 2015;33:2133–40.
 22. Zoppini G, Bergamini C, Bonapace S, et al. Association between 
subclinical left ventricular systolic dysfunction and glycemic control 
in asymptomatic type 2 diabetic patients with preserved left 
ventricular function. J Diabetes Complications 2017;31:1035–40.
 23. Ernande L, Audureau E, Jellis CL, et al. Clinical implications of 
echocardiographic phenotypes of patients with diabetes mellitus. J 
Am Coll Cardiol 2017;70:1704–16.
 24. Marwick TH, Ritchie R, Shaw JE, et al. Implications of underlying 
mechanisms for the recognition and management of diabetic 
cardiomyopathy. J Am Coll Cardiol 2018;71:339–51.
 o
n
 3 July 2018 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2018-000529 on 14 June 2018. Downloaded from 
